XM does not provide services to residents of the United States of America.
J
J

JuliusBaer

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

BNP, UBS show interest in HSBC's German wealth unit, Bloomberg News reports

UPDATE 2-BNP, UBS show interest in HSBC's German wealth unit, Bloomberg News reports Updates July 4 story to add HSBC response in paragraph 7 July 5 (Reuters) - HSBC HSBA.L is attracting initial interest from peers including BNP Paribas SA BNPP.PA and UBS Group AG UBSG.S , for the sale of its German wealth management unit, Bloomberg News reported on Thursday, citing people familiar with the matter.
B
H
U
A
J

BNP, UBS Are Said To Show Interest In HSBC’s German Wealth Unit- Bloomberg News

BRIEF-BNP, UBS Are Said To Show Interest In HSBC’s German Wealth Unit- Bloomberg News July 4 (Reuters) - BNP, UBS ARE SAID TO SHOW INTEREST IN HSBC’S GERMAN WEALTH UNIT- BLOOMBERG NEWS JULIUS BAER GROUP ALSO AMONG THOSE STUDYING BUSINESS, WHICH COULD BE VALUED AT €300 MILLION TO €600 MILLION IN DEAL- BLOOMBERG NEWS Source https://tinyurl.co
B
H
U
J

Roche Holding seen down on plan to halt lung cancer drug trial

BUZZ-Roche Holding seen down on plan to halt lung cancer drug trial ** Shares of Swiss drugmaker Roche Holding ROG.S seen down 2.3% in Julius Baer pre-market trade following its plans to halt trial for lung cancer treatment after 'disappointing' results ** The company said its antibody drug tiragolumab (anti-TIGIT) in combination with its Tecentriq
R
J

Roche to halt trial in latest setback for lung cancer immunotherapy

UPDATE 2-Roche to halt trial in latest setback for lung cancer immunotherapy Rewrites throughout, adds shares in paragraph 4 By Rachel More and Ludwig Burger BERLIN, July 4 (Reuters) - Roche ROG.S will end a lung cancer trial testing its new immunotherapy after the drug did not show a benefit over established treatment Keytruda by Merck & Co MRK.N , casting further doubt on the drug candidate pioneered by the Swiss company.
R
J

Hedge funds reach midyear with mishmash performance

UPDATE 4-Hedge funds reach midyear with mishmash performance Bridgewater Associates' flagship fund up 14.4% through June 26 Hedge funds show mid-to-high single-digit gains Citadel Wellington gains 8.1% Aspect Capital Diversified fund returns 14.3% in year to end June Updates July 3 story with details from Brevan Howard and Dymon Asia Multi-Strategy Investment Fund By Carolina Mandl and Nell Mackenzie NEW YORK/LONDON, July 3 (Reuters) - Hedge funds delivered a mixed first-half performance, with m
N
J
U

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.